Jay Lee, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Los Angeles, CANPI 1952326654
Payments from drug & device makers
Across 337 payments — averaging $2540.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$327K
- Merck$248K
- AstraZeneca$74K
- Regeneron$58K
- Genentech, Inc.$32K
- Genentech USA, Inc.$30K
- plus $87K from 12 others
Across 40 payments — averaging $1753.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$30K
- F. Hoffmann-la Roche AG$24K
- Novartis$10K
- Novartis Pharma AG$6K
What the payments were for
- Consulting fees$254,06555%
- Speaking & faculty fees$113,82425%
- Travel & lodging$86,31219%
- Food & beverage$7,9442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 6 | $327,183 |
| Merck | 95 | $247,806 |
| AstraZeneca | 66 | $74,038 |
| Regeneron | 61 | $58,181 |
| Genentech, Inc. | 18 | $31,739 |
| Genentech USA, Inc. | 26 | $29,989 |
| E.r. Squibb & Sons, L.L.C. | 21 | $29,779 |
| Novartis | 14 | $24,460 |
| F. Hoffmann-la Roche AG | 12 | $16,043 |
| Eli Lilly | 6 | $8,514 |
| AbbVie | 4 | $6,659 |
| Foundation Medicine, Inc. | 1 | $1,081 |
| Zimmer Biomet | 2 | $339 |
| Medtronic | 1 | $150 |
| Daiichi Sankyo Inc. | 1 | $116 |
| Intuitive Surgical | 1 | $28 |
| Pfizer | 1 | $28 |
| Baxter Healthcare | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$51,670
- TECENTRIQ$51,193
- IMFINZI$27,300
- TAGRISSO$24,375
- OPDIVO$16,537
- KEYTRUDA$16,070
- TABRECTA$9,833
- ILARIS$9,386
- Alecensa$9,044
- Enhertu$4,302
- FOUNDATIONONE CDX$1,081
- Non-Covered Product$878
- OSS Orthopedic Salvage System$198
- Signia$150
- RibFix Blu$141
How this compares
$856,155 in reported general payments places this provider in the 95th percentile of 546 thoracic surgery (cardiothoracic vascular surgery) providers in California.
See all thoracic surgery (cardiothoracic vascular surgery) providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 14 | $73 |
Paid to pharmacies, not to this prescriber.
Other thoracic surgery (cardiothoracic vascular surgery) in Los Angeles
- Fernando FleischmanLos Angeles$901K
- Vaughn StarnesLos Angeles$771K
- Harmik SoukiasianLos Angeles$737K
- Abbas ArdehaliLos Angeles$630K
- Richard SheminLos Angeles$392K
- Fardad EsmailianLos Angeles$356K
- Alfredo TrentoLos Angeles$335K
- Raymond LeeLos Angeles$291K
- Anthony KimLos Angeles$215K
- Bryan BurtLos Angeles$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.